Background: Concurrent sensitization to peanut (PN) and tree nuts (TN), the most
FA children exhibited statistically lower Foxp3 and IL-10 gene expression than cells from healthy children, whereas children acquiring tolerance to the food showed significantly higher levels of the Foxp3 gene expression than children with active FA. An inverse correlation between Foxp3 expression and total IgE levels was also found. 14 Peanut and tree nut (TN) allergies are the most dangerous food allergies, and concurrent sensitization to both PN and TN further increases the risk of severe reactions. Although food allergen oral immunotherapy (OIT) has desensitized some patients, many regained reactivity shortly discontinuing OIT. [15] [16] [17] [18] [19] [20] The mechanisms underlying with regained sensitivity, 22 suggesting that DNA methylation status of the Foxp3 locus might be a biomarker predicting clinical tolerance.
OIT modulation of DNA methylation at the IL-4 and IFN-c promoters has not been reported.
Because of significant safety concerns regarding routine use of OIT, [16] [17] [18] [19] [20] 23 several combined treatment approaches have been investigated. OIT plus anti-IgE antibody administration produced more rapid desensitization to milk and egg proteins with fewer and less severe adverse reactions than OIT only. [24] [25] [26] Administration of a probiotic during 18 months of PN OIT did not reduce the incidence of adverse reactions. 27 A safe and effective PN and TN allergy therapy both desensitizes effector cells and induces tolerogenic immunity by reducing Th2 status, and increasing IFN-c and IL- 10 has not yet been developed.
Murine models of FA are useful tools to investigate new treatments, including OIT. 28 Leonard et al. reported that 3 weeks of daily ovomucoid OIT significantly reduced oral egg challenge-induced gastrointestinal reactions (diarrhoea). However, reactions returned 2 weeks post-therapy, and OIT did not result in desensitization of systemic effector cells. 29 Maeta et al. 30 reported that 10-day rush ovomucoid OIT treatment of mildly ovomucoid-allergic mice failed to reduce allergic symptoms and increased vascular permeability, and it further increased total plasma IgE levels and reduced IFN-c/IL-4 and IL-10/IL-4 ratios compared to sham OIT mice. No animal model study of OIT for PN, TN or multiple allergies has been reported.
Food Allergy Herbal Formula 2 (FAHF-2) protects against PN anaphylaxis in murine models, 31 suppresses basophil activation and Th2 cytokine production, and has high safety profile in clinical studies. 32, 33 BF-2 is butanol purified version of (FAHF-2). This formulation addresses the need to reduce the treatment dose burden, which hindered compliance in FAHF-2 human trials. 34 BF2 suppressed anaphylactic reactions, IgE production, mast cell degranulation and modulated Th1 and Th2 cytokine production in a murine PN allergy model at only 20% of the FAHF-2 dose, and the effect was sustainable. 35 BF2 inhibited human B cell IgE production in vitro 10 times more potently than FAHF-2. 35 Some major active compounds including alkaloids and triterpenoids from BF2 have been identified and found to inhibit IgE production, 36 mast cell activation, 37 and inhibited of pro-inflammatory cytokines in allergy 38 and other inflammatory conditions. 39 We, therefore, hypothesized that combining BF2 and multiple PN/TN OIT would be more beneficial then OIT alone. 
| Plasma histamine, serum antibody and cytokine measurements
Plasma histamine, food-specific immunoglobulins and cytokine levels were determined by ELISA as described previously 35 (Supplementary information E methods 3, 4 and 5).
| CpG methylation analysis
Genomic DNA isolated from intestinal tissue was preserved in AllProtect (Qiagen, Valencia, CA, USA) and bisulphite converted prior to pyrosequencing using a Pyromark Q24 system (Qiagen). Methylation status of CpG residual in promoter regions of IL-4, IFN-c and Foxp3 described previously was examined. 43 Detailed information including PCR and sequencing primers is provided in supporting information (E Methods 6).
| Statistical analysis
Data were analysed using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA). One-way ANOVA with Bonferroni post-test was applied to determine significant differences across treatment groups.
Student's t test was used to analyse differences between selected groups. For data that were not normally distributed, Kruskal-Wallis test was used. Spearman correlation was used for regression analysis. P values less than P≤.05 were considered significant. F I G U R E 1 Experiment Protocol. Pre-OIT phase: mice in groups (G) 1-3 were orally sensitized and boosted weekly with a peanut (PN), cashew (CSH) and walnut (WN) mixture and cholera toxin for 5 weeks as indicated. Individual PN, CSH and WN oral challenges were administered at weeks (W) 6, 7 and 8. They were designated PTNA mice. Na€ ıve mice were not sensitized or challenged. Treatment phase: B-FAHF-2 therapy began on w8 (2 days after walnut challenge) and continued throughout OIT. PN/TN OIT was started following 3 weeks of B-FAHF-2 therapy. Day 1 of OIT was the build-up phase. The highest dose safe for all mice (6.25 mg) was chosen as maintenance dose and administered daily for the remainder of 3 weeks. G1, G2 and G3 PTNA mice received water (sham), G2 OIT alone or BF2+OIT, respectively. Post-OIT phase: mice were challenged with a PN/TN cocktail at 1 and 3 weeks post-therapy to evaluate the effect on desensitization, and individual PN, WN and CSH dose-escalating challenges were administered 5-6 weeks post-OIT and given at 3-day intervals to evaluate induction of tolerance. Mice were killed 48 h after the last challenge. Data are from two sets of experiments. PTNA, peanut-and tree nutallergic mice. *indicating that PTNA mice received 1-day rush OIT prior to the 6.5 mg mixture of each peanut/TN maintenance treatment may not be a key biomarker to distinguish the beneficial influence of BF2 in OIT therapy. We next conducted correlation analysis, and data showed that symptom scores were significantly negatively correlated with body temperature (r=À.801, P<.000, Figure 3E ) and positively correlated with plasma histamine levels (r=.733, P<.0001, Figure 3D ), suggesting plasma histamine levels may be a biomarker to distinguish the superior of protection of BF2+OIT therapy over OIT alone. 
| BF2+OIT but not OIT-treated mice exhibited reduced antigen-specific IgE levels
Prior to treatment, all three PN/TN polysensitized mice showed elevated IgE production against PN, NW and CSH ( Figure 5A 
F I G U R E 3
Reactions following 1 week post-OIT challenge with a peanut, cashew and walnut mixture. Symptom scores were determined using the scoring system described in methods (A). Core body temperatures were measured using a rectal probe. Plasma histamine levels were measured using a commercial ELISA kit. (Table 1) . These results demonstrated that BF2+OIT therapy is associated with greater induction of a tolerogenic cytokine profile. Multiple OIT may prove to be an effective approach for this population of patients, 25, 46 but OIT safety and persistence of protection need to be improved. In this study, we for the first time generated a murine model that displayed concurrent PN and TN allergies as evidenced by elevation of IgEs against PN, CSH and WN following concurrent sensitization, and anaphylactic reactions following individual PN and CSH and WN challenges. We previously showed that BF2
provided protection in a PN allergy model. 30 As seen in the PN Figure 6 ) and cumulative symptom scores in (shown in Figure 4C ) following three 50 mg PN, WN and CHS challenges were analysed using Spearman correlation. *P<.05 and **P<.01 (N =10-11 mice/group) models as reported by Leonard et al. 29 , in which desensitization was achieved, but reactivity returned as soon as 2 weeks post-therapy.
In our study, approximately 63% of OIT-treated mice were desensitized at 1 week post-therapy. Although median symptom scores were significantly lower than in sham-treated PTNA mice, some mice developed severe, including one fatal, reactions. Our study differs from a previous OIT study by Maeta 30 in which ovomucoid OIT did not induce protection in a "mild food allergy" model. This might be because a 10-day OIT protocol was used. We, as did Leonard et al. 29 , used a 21-day protocol and also found significant protection in the OIT-alone group. Importantly, we found that BF2+OIT produced greater and more persistent protection than OIT alone. This combined therapy may provide an option for developing an improved OIT regimen for multiple food allergies, in particular concomitant PN and TN allergies. showed that the BF2 active compounds berberine, palmatine and jatrorrhizine directly inhibit mast cell activation by suppressing phosphorylation of Syk, the key signalling event in mast cell/basophil degranulation. In this study, we showed that basophil number reduction was observed in both treated groups, being greater in the BF2+OIT group immediately post-OIT challenge, but the differences between the groups was not statistically significant. Basophil number alone does not determine desensitization status.
Many previous studies found that OIT causes transient elevation of IgE in patients 47, 48, 49 and murine models. 30 Our study also found that OIT alone induced higher levels of IgE immediately after completing therapy. In contrast, combined BF2+OIT prevented OIT increase of antigen-specific IgE. Importantly, BF2+OIT suppression 
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